[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100627730":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":19,"locations":25,"responsibleParty":39,"collaborators":10,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":10,"eligibilityCriteria":49,"healthyVolunteers":45,"sex":50,"minAge":51,"maxAge":10,"enrollmentInfo":52,"targetDuration":55,"studyType":56,"phases":10,"briefSummary":57,"conditions":58,"keywords":10,"overallStatus":27,"whyStopped":10,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},{"fullName":5,"class":6},"Samsung Medical Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"High-grade non-metastatic UTUC prospective cohort",null,"Adult patients (≥19 years) with high-grade non-metastatic upper tract urothelial carcinoma (cT2-T4, cN0-1, M0) who are planned for neoadjuvant chemotherapy followed by radical nephroureterectomy will be enrolled in this single-center prospective observational cohort. Peripheral blood will be collected for ctDNA analysis prior to neoadjuvant chemotherapy and once between 1-6 months after surgery. Clinical, imaging, pathological, and longitudinal follow-up data will be prospectively collected for recurrence and survival monitoring.",[13],"Other: Peripheral blood collection for ctDNA analysis",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"Peripheral blood collection for ctDNA analysis","Peripheral blood samples (20-30 mL) will be collected prior to neoadjuvant chemotherapy initiation and once between 1-6 months after surgery for circulating tumor DNA (ctDNA) analysis. No investigational drug or device is administered. All oncologic treatments are conducted according to standard clinical practice.",[9],[20],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"Jiwoong Yu, MD","CONTACT","+82234103559","jiwoong082.yu@samsung.com",[26],{"facility":5,"status":27,"city":28,"state":10,"zip":10,"country":29,"countryCode":10,"cosmosGeoPoint":30,"geoPoint":35,"contacts":36},"RECRUITING","Seoul","South Korea",{"type":31,"coordinates":32},"Point",[33,34],126.9784,37.566,{"lat":34,"lon":33},[37],{"name":38,"role":22,"phone":23,"phoneExt":10,"email":24},"Jiwoong Yu",{"type":40,"investigatorFullName":41,"investigatorTitle":42,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Byong Chang Jeong","Professor","100627730","korean-prospective-upper-tract-urothelial-carcinoma-cohort-100627730",false,"NCT07452432","Korean Prospective Upper Tract Urothelial Carcinoma Cohort","Prospective Establishment of a Recurrence Monitoring Cohort in Korean Patients With Upper Tract Urothelial Carcinoma","Inclusion Criteria:\n\n* Age ≥ 19 years\n\nHistologically confirmed high-grade upper tract urothelial carcinoma (renal pelvis and\u002For ureter)\n\nClinical stage cT2-T4, cN0-1, M0\n\nPlanned neoadjuvant chemotherapy followed by radical nephroureterectomy\n\nECOG performance status 0-1\n\nAdequate hematologic, hepatic, and renal function\n\nAbility to provide written informed consent\n\nExclusion Criteria:\n\n* Evidence of distant metastasis (M1)\n\nContraindication to cisplatin-based chemotherapy\n\nUncontrolled infection or severe comorbid medical condition\n\nPregnancy or breastfeeding\n\nAny condition that, in the investigator's judgment, makes participation inappropriate","ALL","19 Years",{"count":53,"type":54},300,"ESTIMATED","5 Years","OBSERVATIONAL","This is a single-center, prospective, non-interventional observational cohort study designed to establish a structured recurrence monitoring platform in Korean patients with high-grade non-metastatic upper tract urothelial carcinoma (UTUC).\n\nEligible adult patients scheduled to receive neoadjuvant chemotherapy followed by radical nephroureterectomy will undergo circulating tumor DNA (ctDNA) sampling prior to chemotherapy initiation and once between 1-6 months after surgery.\n\nClinical, imaging, pathological, and longitudinal follow-up data will be prospectively collected to enable long-term monitoring of recurrence and survival outcomes.\n\nThe primary objective is to establish a prospective cohort integrating clinical and molecular data to support future translational research and recurrence prediction modeling in UTUC.",[59],"Urothelial Carcinoma (UC)","2026-02-28",{"date":62,"type":63},"2026-03-05","ACTUAL",{"date":65,"type":63},"2026-01-01",{"date":67,"type":54},"2030-06-01",{"name":5,"class":6},1]